Serum leptin and HOMA score have not been found to be valid indicators in ovarian tumors. However, the present data suggest that low concentrations of IGF-I and IGFBP-3 could be a reliable marker to differentiate benign from malignant ovarian tumors. Further experimental studies are warranted to understand the impact of the IGF-I system in ovarian carcinogenesis.

The renin-angiotensin system (RAS) is involved in cell growth, proliferation and differentiation in bone marrow in an autocrine-paracrine manner, and it modulates normal and neoplastic haematopoietic cell proliferation. This study aimed to assess expressions of the RAS components, renin, angiotensinogen and angiotensin-converting enzyme (ACE), during imatinib mesylate treatment of patients with chronic myeloid leukaemia (CML). Expressions of RAS components were studied in patients with CML at the time of diagnosis (n = 83) and at 3, 6 and 12 months after diagnosis (n = 35) by quantitative real-time polymerase chain reaction. De novo CML patients had increased ACE, angiotensinogen and renin mRNA levels and these expression levels decreased following administration of imatinib. The RAS activities were significantly different among Sokal risk groups of CML, highlighting the altered biological activity of RAS in neoplastic disorders. The results of this study confirm that haematopoietic RAS affects neoplastic cell production, which may be altered via administration of tyrosine kinase inhibitors such as imatinib mesylate.

Artificial intelligence applications and robotic technologies, which are rapidly spreading and widely used throughout the world, are discussed by different disciplines in the literature. The field of tourism draws attention as one of the disciplines in which studies on these issues have been carried out in recent years. In this context, robots come to the fore in the application areas of the tourism sector. However, it is known that there are many artificial intelligence applications that are becoming widespread or likely to become widespread day by day in the tourism sector. From this point of view, in this conceptual study, firstly artificial intelligence applications and robotic technologies were evaluated, the development of these technologies was revealed, then the current technologies used in the tourism and hospitality industry were examined, and as a result, the future of these technologies in the tourism and hospitality industry was discussed. In this context, it can be said that this study, in which the current situation is revealed and sector-experienced writers make inferences for the future, is an important study that can contribute to the literature and industry practitioners.

Background:Dasatinib, a potent BCR‐ABL tyrosine kinase inhibitor (TKI), is approved for the treatment of chronic phase CML (CML‐CP) in the frontline and salvage settings. Notable side effects include pleural effusions and myelosuppression. We previously reported dasatinib 50 mg daily to be active and better tolerated than the approved 100 mg daily dose (CANCER. 2018 Jul 1;124(13):2740–2747).Aims:An update on the efficacy and toxicity profile of lower dose dasatinib 50 mg orally daily in patients with early CML‐CP.Methods:All patients presenting to our institution in early CML‐CP were eligible to participate. Prior TKI therapy for up to 1 month was allowed. Responses were assessed according to the European LeukemiaNet guidelines (Baccarani et al. Blood 2013 122.872:884).Results:From March 2016 to March 2018, 81 patients have been enrolled. Median age is 47 years (20–84). Patients categorized by Sokal risk are: low 53; intermediate 22 and high 6. Median follow‐up is 18 months (9–31). Cumulative response rates (n = 81) over time are shown in the gragh below.At 3 months, 96% patients achieved early molecular response (BCR‐ABL PCR ≤10%). Median time to CCyR was 4.6 months, MMR 6.0 months, MR4.0 11.4 months and MR4.5 12.2 months. Eighteen patients had treatment interruption: pleural effusion 4 (possibly related 3, unrelated 1 due to pneumonia); gastrointestinal bleed 2; thrombocytopenia 3; transaminitis 2; renal dysfunction 1; asthma exacerbation 1; pneumonitis 1; lower extremity edema 1; myalgias 1, and pregnancy 2. Four patients had dose reductions: pleural effusion 3; myalgias 1. Four patients had dasatinib dose increased to 100 mg: lack of CCyR at 6 months, 3; lack of MMR at 12 months, 1. Four patients are off study: no response 2, pneumonitis 1, and insurance 1. None of the patients have transformed or died.Summary/Conclusion:These updated results continue to support dasatinib 50 mg daily as an effective and safe dose for early CML‐CP.image

No abstract